The Israeli pharmaceutical manufacturing giant Teva has agreed a takeover of its US competitor Barr in a deal worth $7.5 billion (£3.75 billion), it announced today.
Teva also assume the $1.5 billion (£750,000) debt held by Barr, in a deal which further strengthens its position as the world’s leading seller of off-patent drugs. The joint company will market over 500 products and would have had combined revenue in 2007 of $11.9 billion (£5.98 billion). “The acquisition of Barr will elevate Teva’s…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
